

**MARKED-UP VERSION OF THE AMENDMENT**

**In the Specification:**

On the first line of the specification after the Title, please amend the following paragraph:

- This application is a continuation-in-part application of copending U.S. Application No. 09/571,388 filed on May 15, 2000, now U.S. Patent No. 6,390,291, which is a continuation-in-part application of Serial No. 09/290,351 filed April 12, 1999, now U.S. Patent No. 6,179,118, the entire contents of both of which are incorporated by reference [; and for which an international application PCT/US99/27851 was filed 23 November 1999; and for which a] , which is a continuation-in-part application of U.S. Application No. 09/216,183 [was] filed December 18, 1998, now U.S. Patent No. 6,119,853.

REMARKS

Applicant notes that the following amendment was first introduced in an Amendment filed pursuant to 37 C.F.R. 1.312 dated January 16, 2003. Although Applicant believes that the above amendment has been entered, a duplicate of such amendment is submitted herewith to ensure such entry. This amendment is filed concurrently with a Request for Continued Examination. The Examiner is encouraged to contact Applicants' undersigned representative at (919) 483-9616 regarding the above.

Respectfully submitted,

Date: 3-12-03



Robert J. Smith  
Reg. No. 40,820  
Attorney for Applicants

GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive  
PO Box 13398  
Research Triangle Park, NC 27709-3398  
Direct Phone (919)483-9616  
Facsimile (919)483- 1988



23347

PATENT TRADEMARK OFFICE